Molecular Partners Ag (MOLN) EBT (2020 - 2026)

Molecular Partners Ag (MOLN) has reported EBT for 7 consecutive years, with -$16784.9 the latest figure, recorded in Q1 2026.

• Quarterly EBT rose 10.02% year-over-year to -$16784.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.9 million (down 31.54% YoY) and the FY2025 annual result came in at -$81.9 million, down 31.56% from the prior year.
• EBT grew to -$16784.9 in Q1 2026 per MOLN's latest filing, from -$81.8 million in the prior quarter.
• Over the last five years, EBT for MOLN reached as high as $127.7 million in Q4 2022 and fell as low as -$81.8 million in Q4 2025.
• A 5-year average of -$6.5 million and a median of -$16784.9 in 2026 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT jumped 1005.57% — and 2023, when it sank 278.7%.
• Year by year, EBT stood at $127.7 million in 2022, then slumped by 156.44% to -$72.1 million in 2023, then advanced by 13.69% to -$62.2 million in 2024, then slumped by 31.56% to -$81.8 million in 2025, then soared by 99.98% to -$16784.9 in 2026.
• According to Business Quant data, EBT over the past three periods registered -$16784.9, -$81.8 million, and -$14796.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.